GlassScriptPhysician profile
Christopher Thomas Bunn
NPI 1164798716
$1,430.00
in general payments reported to CMS, 2019-2025
19 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $212 · 2021: $70.05 · 2022: $233 · 2023: $250 · 2024: $159 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $199.18 | 2022-2024 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.06 | 2019-2025 | Jardiance |
| Abiomed | $139.47 | 2024-2025 | Impella |
| Pfizer INC. | $134.97 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $112.69 | 2019-2024 | |
| Amgen INC. | $109.84 | 2019 | |
| Astellas Pharma US INC | $99.99 | 2020 | |
| Lantheus Medical Imaging, INC. | $90.84 | 2020-2025 | Definity |
| Janssen Pharmaceuticals, INC | $68.71 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $51.76 | 2023-2025 | Cds - Mct/Cem Monitoring, Synergy |
| Novo Nordisk INC | $41.92 | 2023-2024 | Ozempic, Rybelsus |
| Ge Healthcare | $36.55 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.77 | 2019-2025 | Lifevest |
| Livanova USA, INC. | $23.82 | 2023 | Tandemlife |
| Alnylam Pharmaceuticals INC. | $22.85 | 2025 | Onpattro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.49 | 2022 | |
| Scpharmaceuticals INC. | $16.06 | 2025 | |
| Chiesi USA, INC. | $15.79 | 2024 | Kengreal |
| Regeneron Healthcare Solutions, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.